ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron’s Oncology Pipeline in Multiple Cancers | 05.09.22
First-in-class Phase 1 data for two investigational bispecifics in advanced ovarian cancer and advanced MET-altered non-small cell lung cancer (NSCLC) to be presented Additional presentations […]